Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05668585 · ClinicalTrials.gov registry record · Phase 1
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
A Phase 1 study, sponsored by C4 Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT05668585 is a Phase 1 study that has completed, run by C4 Therapeutics. The registered enrollment target is 89 participants.
The verdict
NCT05668585, a Phase 1 study, has completed, sponsored by C4 Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
Interventions
- DRUG Cetuximab
- DRUG Trametinib
- DRUG CFT1946
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2025-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05668585
The ClinicalTrials.gov registry entry for NCT05668585 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C4 Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT05668585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05668585 about?
NCT05668585 is a clinical study titled "A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946...
What is the current status of trial NCT05668585?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2022-12-08. Estimated completion is 2025-11-05.
What interventions are being tested in trial NCT05668585?
The interventions under investigation include: Cetuximab (DRUG), Trametinib (DRUG), CFT1946 (DRUG).
Who is sponsoring clinical trial NCT05668585?
This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.